2025年,全球药企收购活动频发。其中,多家跨国巨头围绕弥补核心产品增长短板、补强细分赛道管线等原因,已展开了多笔超百亿元人民币的收购。默沙东92亿美元收购Cidara Therapeutics11月17日消息,默沙东宣布以92亿美元(约合654亿元人民币)现金收购Cidara Therapeutics,将其处于3期临床试验的主要资产流感预防药物CD388收入囊中。根据公开信息,在传统流感疫苗平均...
Source Link2025年,全球药企收购活动频发。其中,多家跨国巨头围绕弥补核心产品增长短板、补强细分赛道管线等原因,已展开了多笔超百亿元人民币的收购。默沙东92亿美元收购Cidara Therapeutics11月17日消息,默沙东宣布以92亿美元(约合654亿元人民币)现金收购Cidara Therapeutics,将其处于3期临床试验的主要资产流感预防药物CD388收入囊中。根据公开信息,在传统流感疫苗平均...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.